# Modeling polypharmacy side effects with graph convolutional networks

arXiv: https://arxiv.org/abs/1802.00543 · HTML: https://mlsanity.com/paper/1802.00543/

## Key facts

- Cited by 237 papers in the map (data through 14 Oct 2026).
- First posted on arXiv 2 Feb 2018.

## Built on by (most cited first, 30 of 237)

- [Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development](https://mlsanity.com/paper/2102.09548/) (2021)
- [Is Homophily a Necessity for Graph Neural Networks?](https://mlsanity.com/paper/2106.06134/) (2021)
- [Deep Bidirectional Language-Knowledge Graph Pretraining](https://mlsanity.com/paper/2210.09338/) (2022)
- [Towards a Unified Framework for Fair and Stable Graph Representation Learning](https://mlsanity.com/paper/2102.13186/) (2021)
- [Generative Causal Explanations for Graph Neural Networks](https://mlsanity.com/paper/2104.06643/) (2021)
- [CF-GNNExplainer: Counterfactual Explanations for Graph Neural Networks](https://mlsanity.com/paper/2102.03322/) (2021)
- [Evaluating Explainability for Graph Neural Networks](https://mlsanity.com/paper/2208.09339/) (2022)
- [Everything is Connected: Graph Neural Networks](https://mlsanity.com/paper/2301.08210/) (2023)
- [Graph Representation Learning in Biomedicine](https://mlsanity.com/paper/2104.04883/) (2021)
- [OOD-GNN: Out-of-Distribution Generalized Graph Neural Network](https://mlsanity.com/paper/2112.03806/) (2021)
- [Directed Acyclic Graph Neural Networks](https://mlsanity.com/paper/2101.07965/) (2021)
- [A Survey on Hyperdimensional Computing aka Vector Symbolic Architectures, Part II: Applications, Cognitive Models, and Challenges](https://mlsanity.com/paper/2112.15424/) (2021)
- [TCL: Transformer-based Dynamic Graph Modelling via Contrastive Learning](https://mlsanity.com/paper/2105.07944/) (2021)
- [MoCL: Data-driven Molecular Fingerprint via Knowledge-aware Contrastive Learning from Molecular Graph](https://mlsanity.com/paper/2106.04509/) (2021)
- [On the Unreasonable Effectiveness of Feature propagation in Learning on Graphs with Missing Node Features](https://mlsanity.com/paper/2111.12128/) (2021)
- [Theory of Graph Neural Networks: Representation and Learning](https://mlsanity.com/paper/2204.07697/) (2022)
- [Anti-Symmetric DGN: a stable architecture for Deep Graph Networks](https://mlsanity.com/paper/2210.09789/) (2022)
- [DistGNN: Scalable Distributed Training for Large-Scale Graph Neural Networks](https://mlsanity.com/paper/2104.06700/) (2021)
- [Scalable and Adaptive Graph Neural Networks with Self-Label-Enhanced training](https://mlsanity.com/paper/2104.09376/) (2021)
- [Model Stealing Attacks Against Inductive Graph Neural Networks](https://mlsanity.com/paper/2112.08331/) (2021)
- [Shortest Path Networks for Graph Property Prediction](https://mlsanity.com/paper/2206.01003/) (2022)
- [Mitigating Over-Smoothing and Over-Squashing using Augmentations of Forman-Ricci Curvature](https://mlsanity.com/paper/2309.09384/) (2023)
- [A Review of Biomedical Datasets Relating to Drug Discovery: A Knowledge Graph Perspective](https://mlsanity.com/paper/2102.10062/) (2021)
- [DGL-LifeSci: An Open-Source Toolkit for Deep Learning on Graphs in Life Science](https://mlsanity.com/paper/2106.14232/) (2021)
- [Modeling Heterogeneous Hierarchies with Relation-specific Hyperbolic Cones](https://mlsanity.com/paper/2110.14923/) (2021)
- [Probing GNN Explainers: A Rigorous Theoretical and Empirical Analysis of GNN Explanation Methods](https://mlsanity.com/paper/2106.09078/) (2021)
- [Cooperative Graph Neural Networks](https://mlsanity.com/paper/2310.01267/) (2023)
- [Prot2Text: Multimodal Protein's Function Generation with GNNs and Transformers](https://mlsanity.com/paper/2307.14367/) (2023)
- [Graph Lifelong Learning: A Survey](https://mlsanity.com/paper/2202.10688/) (2022)
- [A Survey on Explainability of Graph Neural Networks](https://mlsanity.com/paper/2306.01958/) (2023)

## Abstract (arXiv)

The use of drug combinations, termed polypharmacy, is common to treat patients with complex diseases and co-existing conditions. However, a major consequence of polypharmacy is a much higher risk of adverse side effects for the patient. Polypharmacy side effects emerge because of drug-drug interactions, in which activity of one drug may change if taken with another drug. The knowledge of drug interactions is limited because these complex relationships are rare, and are usually not observed in relatively small clinical testing. Discovering polypharmacy side effects thus remains an important challenge with significant implications for patient mortality. Here, we present Decagon, an approach for modeling polypharmacy side effects. The approach constructs a multimodal graph of protein-protein interactions, drug-protein target interactions, and the polypharmacy side effects, which are represented as drug-drug interactions, where each side effect is an edge of a different type. Decagon is developed specifically to handle such multimodal graphs with a large number of edge types. Our approach develops a new graph convolutional neural network for multirelational link prediction in multimodal networks. Decagon predicts the exact side effect, if any, through which a given drug combination manifests clinically. Decagon accurately predicts polypharmacy side effects, outperforming baselines by up to 69%. We find that it automatically learns representations of side effects indicative of co-occurrence of polypharmacy in patients. Furthermore, Decagon models particularly well side effects with a strong molecular basis, while on predominantly non-molecular side effects, it achieves good performance because of effective sharing of model parameters across edge types. Decagon creates opportunities to use large pharmacogenomic and patient data to flag and prioritize side effects for follow-up analysis.